Deals 25 June 2004
Middletons acted in the successful capital raising and ASX listing of the international biotechnology company CyGenics Ltd with a market capitalisation of just under $70 million on IPO.
Middletons acted in the successful capital raising and ASX listing of the international biotechnology company CyGenics Ltd with a market capitalisation of just under $70 million on IPO. CyGenics is a leader in the development and commercialisation of stem cell related technologies and applications covering tissue banking, tissue engineering, cell growth biomanufacturing, biologics and cell therapy. The fund raising through the IPO is to provide for further business expansion and human clinical trials of the technology. Middletons partners Peter Howard and Andrew Gaffney headed the Middletons team in the listing.
Linklaters has advised on what it said was believed to be the largest project financing of ships to date. The limited recourse financing of four LNG vessels for long-term charter to the RasGas II liquefied natural gas project in Qatar has a total value of US $700 ($997) million. The firm advised the group of six mandated lead arrangers: ANZ Investment Bank, BNP Paribas, Crédit Agricole Indosuez, Société Générale, Sumitomo Mitsui Banking Corporation Europe Limited and The Bank of Tokyo-Mitsubishi, Ltd. The Linklaters team was led by projects partner Jeremy Gewirtz, assisted by Christopher Bradley, David Charlier and Dimitri Papaefstratiou.